Skip to main content

Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders

Buy Article:

$43.00 plus tax (Refund Policy)

Kopala L, Smith G, Malla A, Williams R, Love L, Talling D, Balshaw R. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.

Acta Psychiatr Scand 2006: 113 (Suppl. 430): 29–39. © 2006 Blackwell Munksgaard. Objective: 

To determine how the use of the newer, so called atypical antipsychotic medications, effects the pharmacoeconomic treatment burden of schizophrenia and related conditions and to provide a clear comparison of the costs and risks associated with these atypical drugs. Method: 

In this 2-year, open-label, prospective study, resource utilization (RU) data were collected on 160 patients with these conditions. A comparison between risks and costs was performed by combining the generalized CNOMSS data on both economic factors and risk assessments. Results: 

The main findings of the study were that the total adjusted 1- and 2-year costs were lowest for quetiapine. Drug acquisition costs were lowest for risperidone for both the 1- and 2-year cohorts. Clozapine use was predictably associated with the highest overall and medication costs at both 1 and 2 years. Conclusion: 

Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cost analysis; prognosis; schizophrenia

Document Type: Research Article

Affiliations: 1: Department of Psychiatry, University of British Columbia, Vancouver, BC 2: Department of Psychiatry, McGill University, Montreal, QC 3: Syreon Corporation, Vancouver, BC, Canada

Publication date: 2006-05-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more